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with control) with stretching or strengthening
exercises, mechanical traction, or TENS. The
panel found insufficient evidence to support the
use of mechanical traction for patient global
improvement and return to work. Therapeutic
exercise—including stretching, strengthening,
and mobility exercises—significantly reduces
pain and improves function for chronic low back
pain (longer than 12 weeks); but there was no
clinical benefit in facilitating return to work. No
specific comments on yoga appeared in their
recommendations.
The US Preventive Services Task Force reports
that evidence is insufficient to recommend for or
against counseling patients to exercise to prevent
low back pain; it makes no mention about yoga.9
Nathan Graves, MD, Martin Krepcho, PhD, Helen
G. Mayo, MLS, University of Texas Southwestern Medical
Center at Dallas
■ CLINICAL COMMENTARY:
Information suggests yoga—and all 
exercise—effective for low back pain
Good evidence supports the concept that activ-
ity is more effective than bed rest for acute low
back pain. Recent studies in the rehabilitation
and physical therapy literature have empha-
sized core stability exercises for acute and
chronic back pain. As balance, strength, and
flexibility improve, the episodes and intensity
of acute low back pain diminish.  
It stands to reason that activities such as
hatha yoga that improve muscular strength,
flexibility, and balance would similarly improve
function and decrease low back pain. The
available information would lead me to recom-
mend yoga for my patients with low back pain.
Yoga may well be effective, and no reports in
the literature show harm.
John Hill, MD, Rose Family Medicine Residency,
Denver, Colo
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Do inhaled beta-agonists
control cough in URIs 
or acute bronchitis?
■ EVIDENCE-BASED ANSWER
Patients who receive inhaled beta-agonists for
cough due to acute upper respiratory infections
(URI) are just as likely to report a productive
cough at 7 days compared with patients treated
with placebo (strength of recommendation
[SOR]: A, based on a systematic review).
One trial, however, showed a reduction in
overall cough at 7 days (number needed to treat
[NNT]=3, SOR: B, a small randomized con-
trolled trial), and another trial found a reduc-
tion in overall symptom score in smokers and
those with wheezing on initial exam (SOR: B,
based on a small randomized controlled trial).
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■ EVIDENCE SUMMARY
No studies of inhaled beta-agonists have been con-
ducted with patients who have an explicit diagno-
sis of acute cough due to URI. While some clini-
cians feel a distinction between URI and acute
bronchitis should be made, there is significant
overlap between these diagnoses in clinical prac-
tice, as well as in the available studies. 
A systematic review looking at beta-agonists
for acute bronchitis included the clinical diag-
noses of both acute bronchitis and acute cough
because a standard definition of bronchitis is
lacking.1 Only two trials in this review examined
inhaled beta-agonists. When results from these
trials were combined for the outcome of produc-
tive cough at 7 days, inhaled beta-agonists
showed no benefit. However, the authors note
that details of the individual trials may help to
clarify the effect of inhaled beta-agonists.
One trial, a randomized controlled trial of
adult patients with acute bronchitis in 2 com-
munity-based family practices, compared 23
patients receiving albuterolin a multidose
inhaler (MDI) with 23 patients receiving place-
bo inhaler.2 Patients were also randomized to
receive erythromycin or placebo tablets.
Patients with pneumonia or a history of asthma
or chronic obstructive pulmonary disease
(COPD) were excluded. At 7 days, 61% of
patients in the albuterol group reported cough
compared with 91% in the control group (P=.02,
NNT=3). No statistically significant difference
was seen in productive cough or night cough.
Smokers responded to inhaled albuterol similar-
ly to nonsmokers. Erythromycin had no effect
on cough and side effects were similar among
all groups.
The other trial was a randomized controlled
trial of 80 adults with cough due to acute respi-
ratory infection; it compared fenoterol aerosol 4
times daily with placebo.3 Inhaled fenoterol is
not available in the US but is similar to
albuterol. This study showed no difference in
cough at 7 days (relative risk [RR]=0.83; 95%
confidence interval [CI], 0.52–1.30). In a sub-
group analysis, however, smokers and those
wheezing on initial exam had lower overall
symptom scores when treated with fenoterol.
■ RECOMMENDATIONS FROM OTHERS
We were unable to find any guidelines on the
use of albuterol via MDI for cough from bron-
chitis or URIs. 
■ CLINICAL COMMENTARY:
Inhaled beta-agonists may aid symptoms;
other outcomes may not be improved
Even without a history of lung disease,
patients presenting with cough due to acute
respiratory illness and with evidence of air-
flow obstruction (wheezing) appear to receive
symptom relief from inhaled beta-agonists.
Smokers may be another subgroup who bene-
fit from treatment. However, important
patient-oriented outcomes (such as reduced
need for over-the-counter medicines, general
well being, and return to work) do not
improve. If using inhaled albuterol to treat
acute cough in practice, one must also con-
sider the financial costs and adverse effects
associated with treatment.
Mary Maniscalco Stephens, MD, MPH, East
Tennessee State University, Johnson City, TN;
Joan Nashelsky, MLS, Family Practice Inquiries Network,
Inc, Iowa City, IA
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With beta-agonists, outcomes such
as need for OTC medications and
return to work do not improve
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